Identification of small molecule inhibitors of amyloid β-induced neuronal apoptosis acting through the imidazoline I2 receptor

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9838-9846

  Montolio, Marisol ^a   Gregori Puigjané, Elisabet ^a   Pineda, David ^a   Mestres, Jordi ^a   Navarro, Pilar ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID BETA PROTEIN; DIZOCILPINE; IMIDAZOLINE I2 RECEPTOR; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT;

ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; ENZYME ACTIVATION; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN DENATURATION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; CELLS, CULTURED; EMBRYO, MAMMALIAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HIPPOCAMPUS; IMIDAZOLINE RECEPTORS; IN SITU NICK-END LABELING; MICE; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84870019698     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301055g     Document Type: Article

References (39)

1. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer Oncogene 2007, 26, 3279-3290
2. Harper, S. J.; Wilkie, N. MAPKs: New targets for neurodegeneration Expert Opin. Ther. Targets 2003, 7, 187-200
3. Peng, S.; Zhang, Y.; Zhang, J.; Wang, H.; Ren, B. ERK in learning and memory: A review of recent research Int. J. Mol. Sci. 2010, 11, 222-232
4. Webster, B.; Hansen, L.; Adame, A.; Crews, L.; Torrance, M.; Thal, L.; Masliah, E. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease J. Neuropathol. Exp. Neurol. 2006, 65, 142-151
5. Dineley, K. T.; Westerman, M.; Bui, D.; Bell, K.; Ashe, K. H.; Sweatt, J. D. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease J. Neurosci. 2001, 21, 4125-4133
6. Medina, M. G.; Ledesma, M. D.; Dominguez, J. E.; Medina, M.; Zafra, D.; Alameda, F.; Dotti, C. G.; Navarro, P. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation EMBO J. 2005, 24, 1706-1716
7. Cummings, J. L. Alzheimer's disease N. Engl. J. Med. 2004, 351, 56-67
8. Walsh, D. M.; Selkoe, D. J. A beta oligomers - A decade of discovery J. Neurochem. 2007, 101, 1172-1184
9. Jang, J. H.; Surh, Y. J. Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway Free Radical Biol. Med. 2005, 38, 1604-1613
10. Echeverria, V.; Ducatenzeiler, A.; Dowd, E.; Janne, J.; Grant, S. M.; Szyf, M.; Wandosell, F.; Avila, J.; Grimm, H.; Dunnett, S. B.; Hartmann, T.; Alhonen, L.; Cuello, A. C. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons Neuroscience 2004, 129, 583-592
11. Collen, D.; Lijnen, H. R. Tissue-type plasminogen activator: a historical perspective and personal account J. Thromb. Haemostasis 2004, 2, 541-546
12. Wong, E. H.; Kemp, J. A.; Priestley, T.; Knight, A. R.; Woodruff, G. N.; Iversen, L. L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 7104-7108
13. Parsons, C. G.; Gruner, R.; Rozental, J.; Millar, J.; Lodge, D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan) Neuropharmacology 1993, 32, 1337-1350
14. Gregori-Puigjane, E.; Mestres, J. SHED: Shannon entropy descriptors from topological feature distributions J. Chem. Inf. Model. 2006, 46, 1615-1622
15. Gallastegui, E.; Marshall, B.; Vidal, D.; Sanchez-Duffhues, G.; Collado, J. A.; Alvarez-Fernandez, C.; Luque, N.; Terme, J. M.; Gatell, J. M.; Sanchez-Palomino, S.; Munoz, E.; Mestres, J.; Verdin, E.; Jordan, A. Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1 J. Virol. 2012, 86, 3795-3808
16. Gregori-Puigjané, E.; Garriga-Sust, R.; Mestres, J. Indexing molecules with chemical graph identifiers J. Comput. Chem. 2011, 32, 2638-2646
17. Rapoport, M.; Ferreira, A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons J. Neurochem. 2000, 74, 125-133
18. Youdim, M. B.; Buccafusco, J. J. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases J. Neural Transm. 2005, 112, 519-537
19. Laggner, C.; Kokel, D.; Setola, V.; Tolia, A.; Lin, H.; Irwin, J. J.; Keiser, M. J.; Cheung, C. Y.; Minor, D. L., Jr.; Roth, B. L.; Peterson, R. T.; Shoichet, B. K. Chemical informatics and target identification in a zebrafish phenotypic screen Nat. Chem. Biol. 2011, 8, 144-146
20. Vidal, D.; Mestres, J. In silico receptorome screening of antipsychotic drugs Mol. Inf. 2010, 29, 543-551
21. Flachner, B.; Lorincz, Z.; Carotti, A.; Nicolotti, O.; Kuchipudi, P.; Remez, N.; Sanz, F.; Tovari, J.; Szabo, M. J.; Bertok, B.; Cseh, S.; Mestres, J.; Dorman, G. A chemocentric approach to the identification of cancer targets PLoS One 2012, 7, e35582
22. Areias, F. M.; Brea, J.; Gregori-Puigjane, E.; Zaki, M. E.; Carvalho, M. A.; Dominguez, E.; Gutierrez-de-Teran, H.; Proenca, M. F.; Loza, M. I.; Mestres, J. In silico directed chemical probing of the adenosine receptor family Bioorg. Med. Chem. 2010, 18, 3043-3052
23. Mestres, J.; Seifert, S. A.; Oprea, T. I. Linking pharmacology to clinical reports: Cyclobenzaprine and its possible association with serotonin syndrome Clin. Pharmacol. Ther. 2011, 90, 662-665
24. Sun, Z.; Chang, C. H.; Ernsberger, P. Identification of IRAS/Nischarin as an I1-imidazoline receptor in PC12 rat pheochromocytoma cells J. Neurochem. 2007, 101, 99-108
25. Garcia-Sevilla, J. A.; Escriba, P. V.; Walzer, C.; Bouras, C.; Guimon, J. Imidazoline receptor proteins in brains of patients with Alzheimer's disease Neurosci. Lett. 1998, 247, 95-98
26. Ferrari, F.; Fiorentino, S.; Mennuni, L.; Garofalo, P.; Letari, O.; Mandelli, S.; Giordani, A.; Lanza, M.; Caselli, G. Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain J. Pain Res. 2011, 4, 111-125
27. Dardonville, C.; Fernandez-Fernandez, C.; Gibbons, S. L.; Ryan, G. J.; Jagerovic, N.; Gabilondo, A. M.; Meana, J. J.; Callado, L. F. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites Bioorg. Med. Chem. 2006, 14, 6570-6580
28. Treder, A. P.; Andruszkiewicz, R.; Zgoda, W.; Walkowiak, A.; Ford, C.; Hudson, A. L. New imidazoline/alpha(2)-adrenoceptors affecting compounds-4(5)-(2-aminoethyl)imidazoline (dihydrohistamine) derivatives. Synthesis and receptor affinity studies Bioorg. Med. Chem. 2011, 19, 156-167
29. Tomassoli, I.; Ismaili, L.; Pudlo, M.; de Los, R. C.; Soriano, E.; Colmena, I.; Gandia, L.; Rivas, L.; Samadi, A.; Marco-Contelles, J.; Refouvelet, B. Synthesis, biological assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors, and Ca channel antagonists Eur. J. Med. Chem. 2011, 46, 1-10
30. Bolea, I.; Juarez-Jimenez, J.; de Los, R. C.; Chioua, M.; Pouplana, R.; Luque, F. J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl- 1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease J. Med. Chem. 2011, 54, 8251-8270
31. National Institute for Health and Clinical Excellence. Donezepil,galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. NICE technology appraisal guidance 217, (2011) (http://guidance.nice.org.uk/TA217).
32. Jiang, S. X.; Zheng, R. Y.; Zeng, J. Q.; Li, X. L.; Han, Z.; Hou, S. T. Reversible inhibition of intracellular calcium influx through NMDA receptors by imidazoline I(2) receptor antagonists Eur. J. Pharmacol. 2010, 629, 12-19
33. Soto, J.; Ulibarri, I.; Jauregui, J. V.; Ballesteros, J.; Meana, J. J. Dissociation between I2-imidazoline receptors and MAO-B activity in platelets of patients with Alzheimer's type dementia J. Psychiatr. Res. 1999, 33, 251-257
34. McDonald, G. R.; Olivieri, A.; Ramsay, R. R.; Holt, A. On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B Pharmacol. Res. 2010, 62, 475-488
35. Spires, T. L.; Hyman, B. T. Transgenic models of Alzheimer's disease: Learning form animals NeuroRX 2005, 2, 423-437
36. R. Lalonde, R.; Fukuchi, K.; Strazielle, C. APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD) Neurosci. Biobehav. Rev. 2012, 36, 1357-1375
37. Duff, K.; Suleman, F. Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? Briefings Funct. Genomics Proteomics 2004, 3, 47-59
38. Chemotargets SL. http://www.certara.com/products/predictfx/, 2012.
39. Goslin, K.; Banker, G. Culturing Nerve Cells; MIT Press: Cambridge, MA, 1991; pp 251-281.